What’s Happening With Roche (RHHBY) Stock?
Swiss pharma giant Roche’s stock (OTCMKTS: RHHBY) was up 6% in yesterday’s trading session. This can be attributed to Biogen’s success with its Alzheimer’s treatment – Lecanemab – in late-stage clinical trials. Lecanemab removed built-up plaque in the brain called beta amyloid, resulting in a cognitive benefit for patients with early-stage Alzheimer’s disease.  Now, Roche is also testing an Alzheimer’s treatment with a similar objective to cut down on beta amyloid levels in the brain. While Biogen’s share rose a stellar 40% yesterday, the development helped some other pharmaceutical stocks with Alzheimer’s treatments in the pipeline, including Roche, Eli Lilly, and Prothena.
Despite yesterday’s move, Roche stock is down 24% this year, in line with the decline in the broader S&P500 index. The company’s diagnostics business, which led the revenue growth since the beginning of the pandemic due to high demand for Covid-19 testing, is expected to see a decline in sales in the near term. For perspective, Diagnostics sales surged 49% between 2019 and 2021. Roche also sells Ronapreve – a treatment for Covid-19, developed by Regeneron and distributed by Roche outside the U.S. The Covid-19-related products accounted for $7 billion of the $72 billion sales for Roche in 2021. There have been rising concerns over the future growth drivers for Roche, given that its Covid-19-related products will see a fall in sales in the near term. A sell-off in broader markets due to higher inflation and rising interest rates slowing the economic growth isn’t helping Roche stock either.
That said, Roche’s pharmaceutical business is seeing a steady rise in sales, benefiting from the continued uptick of its relatively new drugs, including Perjeta, Kadcyla, Alecensa, Tecentriq, Actemra, Hemlibra, and Ocrevus, a trend expected to continue going forward. See our dashboard on Roche Revenue for an overview of Roche’s business model and how its revenues are likely to trend.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
|S&P 500 Return||-6%||-22%||66%|
|Trefis Multi-Strategy Portfolio||-9%||-23%||203%|
 Month-to-date and year-to-date as of 9/29/2022
 Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
- Biogen’s Press Release, Sep 27, 2022 [↩]